MSB 1.56% 97.5¢ mesoblast limited

Ann: Appendix 4C Quarterly Activity Report, page-27

  1. 15,547 Posts.
    lightbulb Created with Sketch. 5610
    Getting stockpiles ready ... Hmmm .... they also increased manufacturing in the lead up to Remestemcel-L outcome for sr-GVHD "in anticipation" and we all know how that turned out ....

    .... surely this time around they are increasing stockpiles based on something concrete from either NIH/FDA or why use words like "anticipation for product launch of remestemcel-L" especially with the ambulance chaser lurking in the background ?

    I guess we will know more when they tell us .... I would also add there are a few tidbits in there regardless of some of the comments I have read this morning .... is it earth shattering - not really but it is progress ... GLTAH


    Product manufacturing & operating costs and manufacturing commercialization payments were US$8.1 million for the current quarter, the majority being for commercial manufacturing and inventory build in anticipation for product launch of remestemcel-L.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.